Radiopharmaceutical Archives -

The inaugural Targeted Radiopharmaceuticals Summit US will bring together a worldwide community of specialists to address long-standing challenges in radiopharmaceutical

Targeted Radiopharmaceuticals Summit US (TRP US)

https://pharmaphorum.com/events/targeted-radiopharmaceuticals-summit-us-trp-us/

News/ News/ News/ Oncology/ Sales and Marketing

Manufacturing foul-up hits Novartis’ radioligand business

Phil Taylor Lutathera, manufacturing, Novartis, Oncology, Pluvicto, Radiopharmaceutical 0 Comment

Novartis has shut down production of its radioligand therapies – one of its key growth areas – at

Manufacturing foul-up hits Novartis’ radioligand business

https://pharmaphorum.com/news/manufacturing-foul-up-hits-novartis-radioligand-business/

Market Access/ News/ News

UK grants early access to Novartis’ prostate cancer radioligand

Phil Taylor Advanced Accelerator Applications, Early Access to Medicines Scheme, MHRA, Novartis, Pluvicto, Prostate cancer, Radiopharmaceutical, UK 0 Comment

The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy

UK grants early access to Novartis’ prostate cancer radioligand

https://pharmaphorum.com/news/uk-grants-early-access-to-novartis-prostate-cancer-radioligand/

News/ News/ Oncology

Novartis gets first OK for radioligand Pluvicto in prostate cancer

Phil Taylor Novartis, Oncology, Pluvicto, Prostate cancer, Radiopharmaceutical, regulatory approval 0 Comment

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has

Novartis gets first OK for radioligand Pluvicto in prostate cancer

https://pharmaphorum.com/news/novartis-gets-first-ok-for-radioligand-pluvicto-in-prostate-cancer/

News/ News/ Oncology

Belgium’s Precirix raises €80m to fund radiopharma aspirations

Phil Taylor Belgium, Biotech, financing, Oncology, Precirix, Radiopharmaceutical 0 Comment

Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple

Belgium’s Precirix raises €80m to fund radiopharma aspirations

https://pharmaphorum.com/news/belgiums-precirix-raises-e80m-to-fund-radiopharma-aspirations/

News/ News/ Oncology

Bayer props up sagging radionuclide business with Noria acquisition

Phil Taylor Bayer, M&A, Oncology, Prostate cancer, radionuclide, Radiopharmaceutical 0 Comment

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide

Bayer props up sagging radionuclide business with Noria acquisition

https://pharmaphorum.com/news/bayer-props-up-sagging-radionuclide-business-with-noria-acquisition/

News/ News/ Oncology

ASCO21: Novartis’ prostate cancer radiotherapy extends survival

Phil Taylor 177Lu-PSMA-617, ASCO 2021, Novartis, Oncology, Prostate cancer, Radiopharmaceutical 0 Comment

Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men

ASCO21: Novartis’ prostate cancer radiotherapy extends survival

https://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/

Artifical intelegence DNA molecule. DNA is converted into a binary code. Concept binary code genome. Abstract technology science, concept artifical Dna. 3D illustration

News/ News/ Oncology

Novartis expands in radio-oncology again with $1.3bn Artios alliance

Phil Taylor Artios, Novartis, Oncology, partnering, precision medicine, radiology, Radiopharmaceutical 0 Comment

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus

Novartis expands in radio-oncology again with $1.3bn Artios alliance

https://pharmaphorum.com/news/novartis-expands-in-radio-oncology-again-with-1-3bn-artios-alliance/

News/ News/ R&D

Novartis builds radio-oncology pipeline with iTheranostics deal

Phil Taylor iTheranostics, Novartis, Oncology, radiology, Radiopharmaceutical 0 Comment

Novartis has added to its pipeline of radiopharmaceuticals once again, licensing a series of agents from iTheranostics that

Novartis builds radio-oncology pipeline with iTheranostics deal

https://pharmaphorum.com/news/novartis-builds-radio-oncology-pipeline-with-itheranostics-deal/

Trending

Radiopharmaceutical

Login